FOXG1 Gene Therapy Patent - Viral Vectors
Summary
USPTO published patent application US20260091140A1 for gene therapy constructs and viral vectors treating FOXG1 haploinsufficiency syndrome. Invented by Sarah Elizabeth Sinnett, the application (No. 19346144) includes FOXG1 encoding nucleic acids with miRNA regulatory elements to limit overexpression in vivo.
What changed
USPTO published patent application US20260091140A1 on April 2, 2026, covering expression constructs and viral vectors for FOXG1 gene therapy. The application (No. 19346144, filed September 30, 2025) includes CPC classifications in A61K (therapeutic preparations), A61P (neurological preparations A61P 25/08), and C12N (viral vectors), indicating therapeutic applications for FOXG1 haploinsufficiency syndrome.
Inventors and companies developing gene therapies should review the published claims to assess freedom-to-operate considerations. Competitors in the FOXG1 therapy space should monitor prosecution of this application to identify potential blocking patents. No immediate compliance actions or deadlines are required for this publication.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
GENE THERAPY FOR FOXG1 SYNDROME
Application US20260091140A1 Kind: A1 Apr 02, 2026
Inventors
Sarah Elizabeth Sinnett
Abstract
Provided herein are expression constructs and viral vectors for use as gene therapies for FOXG1 haploinsufficiency. In various aspects, the expression constructs comprise a FOXG1 encoding nucleic acid and one or more miRNA regulatory elements that limit overexpression in vivo.
CPC Classifications
A61K 48/0058 A61K 38/1709 A61P 25/08 C12N 15/86 C12N 2750/14143 C12N 2830/50
Filing Date
2025-09-30
Application No.
19346144
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.